PURE Bioscience Reports Fiscal First Quarter 2025 Financial Results
PURE Bioscience (OTCQB: PURE) reported financial results for fiscal Q1 2025 ended October 31, 2024. Net product sales decreased to $555,000 from $718,000 in the same quarter last year, primarily due to budgetary constraints of a major customer. The company's net loss improved slightly to $689,000 compared to $735,000 in Q1 2024. Net loss per share remained stable at ($0.01).
CEO Robert Bartlett noted that while the company continues to develop its business strategy with key distributors, the process is taking longer than expected. PURE is investing resources in onboarding new distributors, training, and marketing initiatives to expand their product offerings across the food and beverage industry.
PURE Bioscience (OTCQB: PURE) ha riportato i risultati finanziari per il primo trimestre fiscale del 2025, terminato il 31 ottobre 2024. Le vendite nette di prodotti sono diminuite a 555.000 dollari rispetto ai 718.000 dollari dello stesso trimestre dell'anno scorso, principalmente a causa delle restrizioni di bilancio di un cliente importante. La perdita netta dell'azienda è leggermente migliorata, attestandosi a 689.000 dollari rispetto ai 735.000 dollari del primo trimestre del 2024. La perdita netta per azione è rimasta stabile a ($0,01).
Il CEO Robert Bartlett ha osservato che, mentre l'azienda continua a sviluppare la propria strategia commerciale con i distributori chiave, il processo sta richiedendo più tempo del previsto. PURE sta investendo risorse nell'inserimento di nuovi distributori, nella formazione e nelle iniziative di marketing per espandere le proprie offerte di prodotto nell'industria alimentare e delle bevande.
PURE Bioscience (OTCQB: PURE) reportó resultados financieros para el primer trimestre fiscal de 2025 que terminó el 31 de octubre de 2024. Las ventas netas de productos disminuyeron a $555,000 desde $718,000 en el mismo trimestre del año pasado, principalmente debido a restricciones presupuestarias de un cliente importante. La pérdida neta de la compañía mejoró ligeramente a $689,000 en comparación con $735,000 en el primer trimestre de 2024. La pérdida neta por acción se mantuvo estable en ($0.01).
El CEO Robert Bartlett mencionó que, aunque la compañía sigue desarrollando su estrategia comercial con distribuidores clave, el proceso está tomando más tiempo del esperado. PURE está invirtiendo recursos en la incorporación de nuevos distribuidores, la capacitación y las iniciativas de marketing para expandir su oferta de productos en la industria de alimentos y bebidas.
PURE Bioscience (OTCQB: PURE)는 2024년 10월 31일에 종료된 2025 회계 연도 1분기의 재무 결과를 보고했습니다. 제품의 순판매액은 지난해 동일 분기의 718,000달러에서 555,000달러로 감소했으며, 이는 주요 고객의 예산 제한 때문에 발생한 결과입니다. 회사의 순손실은 2024년 1분기 735,000달러에서 689,000달러로 약간 개선되었습니다. 주당 순손실은 ($0.01)로 안정적으로 유지되었습니다.
CEO 로버트 바틀렛은 회사가 주요 유통업체와 비즈니스 전략을 계속 개발하고 있지만, 이 과정이 예상보다 더 오래 걸리고 있다고 언급했습니다. PURE는 새로운 유통업체의 온보딩, 교육 및 마케팅 이니셔티브에 자원을 투자하여 식음료 산업 전반에 걸쳐 제품 범위를 확장하고 있습니다.
PURE Bioscience (OTCQB: PURE) a publié ses résultats financiers pour le premier trimestre de l'exercice 2025, qui s'est terminé le 31 octobre 2024. Les ventes nettes de produits ont diminué à 555 000 $ contre 718 000 $ au cours du même trimestre de l'année précédente, principalement en raison de contraintes budgétaires d'un client majeur. La perte nette de l'entreprise s'est légèrement améliorée, atteignant 689 000 $ contre 735 000 $ au premier trimestre 2024. La perte nette par action est restée stable à ($0,01).
Le PDG Robert Bartlett a fait remarquer que, bien que l'entreprise continue de développer sa stratégie commerciale avec des distributeurs clés, le processus prend plus de temps que prévu. PURE investit des ressources dans l'intégration de nouveaux distributeurs, la formation et des initiatives marketing pour étendre son offre de produits dans l'industrie alimentaire et des boissons.
PURE Bioscience (OTCQB: PURE) berichtete über die finanziellen Ergebnisse für das erste Quartal 2025, das am 31. Oktober 2024 endete. Der Nettoumsatz sank auf 555.000 $ von 718.000 $ im gleichen Quartal des Vorjahres, was hauptsächlich auf Haushaltsbeschränkungen eines großen Kunden zurückzuführen ist. Der Nettoverlust des Unternehmens verbesserte sich leicht auf 689.000 $ im Vergleich zu 735.000 $ im ersten Quartal 2024. Der Nettoverlust pro Aktie blieb stabil bei ($0,01).
CEO Robert Bartlett merkte an, dass das Unternehmen zwar weiterhin seine Geschäftsstrategie mit wichtigen Distributoren entwickelt, der Prozess jedoch länger dauert als erwartet. PURE investiert Ressourcen in die Einarbeitung neuer Distributoren, Schulungen und Marketinginitiativen, um ihr Produktangebot in der Lebensmittel- und Getränkeindustrie auszubauen.
- Net loss improved by $46,000 year-over-year
- Strategic expansion of distributor network in progress
- Diversification efforts across food and beverage industry
- Net product sales declined 22.7% year-over-year ($163,000 decrease)
- Loss of significant revenue from major customer due to budget constraints
- Distribution expansion taking longer than expected
- Continued net losses ($689,000 in Q1)
Summary of Results – Fiscal First Quarter Operations
-
Net product sales were
and$555,000 for the fiscal first quarters ended October 31, 2024 and 2023, respectively. The decrease of$718,000 was attributable to budgetary constraints of a large end-use customer.$163,000 -
Net loss for the fiscal first quarter ended October 31, 2024, was
, compared to$689,000 for the fiscal first quarter ended October 31, 2023.$735,000 -
Net loss, excluding share-based compensation, for the fiscal first quarter ended October 31, 2024, was
, compared to$632,000 for the fiscal first quarter ended October 31, 2023.$655,000 -
Net loss per share was (
) for the fiscal first quarter ended October 31, 2024 and 2023, respectively.$0.01
Robert Bartlett, Chief Executive Officer, stated, “To expand on my recent comment from October 29th, we are continuing to diligently grow our business strategy with key distributors. Although this process is taking longer than expected, it allows us to broaden our product offerings across a larger customer base in the food and beverage industry. Significant resources are being dedicated to onboarding new distributors, providing the necessary training, and ensuring the proper marketing of our products, which will continue into 2025. This year’s first-quarter revenue was anticipated to be lower than the previous year due to an unexpected interruption in the flow of products to one of our major customers in 2024 and the lack of replacement revenue thus far,” concluded Bartlett.
About PURE Bioscience, Inc.
PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors. PURE continues to focus on developing and commercializing our proprietary antimicrobial products, primarily in the food and beverage industry. We provide solutions to combat the health and environmental challenges of pathogens and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. PURE’s mailing address is 771 Jamacha Rd. #512,
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2024 and Form 10-Q for the fiscal first quarter ended October 31, 2024. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Bioscience, Inc. |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
|
|
October 31, 2024 |
|
|
July 31, 2024 |
|
||
|
|
(Unaudited) |
|
|
|
|
||
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
346,000 |
|
|
$ |
349,000 |
|
Accounts receivable |
|
|
371,000 |
|
|
|
298,000 |
|
Inventories, net |
|
|
72,000 |
|
|
|
56,000 |
|
Restricted cash |
|
|
75,000 |
|
|
|
75,000 |
|
Prepaid expenses |
|
|
47,000 |
|
|
|
27,000 |
|
Total current assets |
|
|
911,000 |
|
|
|
805,000 |
|
Property, plant and equipment, net |
|
|
13,000 |
|
|
|
13,000 |
|
Total assets |
|
$ |
924,000 |
|
|
$ |
818,000 |
|
Liabilities and stockholders’ deficiency |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
718,000 |
|
|
$ |
601,000 |
|
Accrued liabilities |
|
|
193,000 |
|
|
|
132,000 |
|
Total current liabilities |
|
|
911,000 |
|
|
|
733,000 |
|
Long-term liabilities |
|
|
|
|
|
|
|
|
Convertible notes payable to related parties |
|
|
3,509,000 |
|
|
|
2,949,000 |
|
Total long-term liabilities |
|
|
3,509,000 |
|
|
|
2,949,000 |
|
Total liabilities |
|
|
4,420,000 |
|
|
|
3,682,000 |
|
Commitments and contingencies |
|
|
|
|
|
|
|
|
Stockholders’ deficiency |
|
|
|
|
|
|
|
|
Preferred stock, |
|
|
— |
|
|
|
— |
|
Common stock, |
|
|
1,119,000 |
|
|
|
1,119,000 |
|
Additional paid-in capital |
|
|
132,669,000 |
|
|
|
132,612,000 |
|
Accumulated deficit |
|
|
(137,284,000 |
) |
|
|
(136,595,000 |
) |
Total stockholders’ deficiency |
|
|
(3,496,000 |
) |
|
|
(2,864,000 |
) |
Total liabilities and stockholders’ deficiency |
|
$ |
924,000 |
|
|
$ |
818,000 |
|
PURE Bioscience, Inc. |
||||||||
Condensed Consolidated Statements of Operations |
||||||||
(Unaudited) |
||||||||
|
|
|
|
|
||||
|
|
Three months ended |
|
|||||
|
|
October 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Net product sales |
|
$ |
555,000 |
|
|
$ |
718,000 |
|
Royalty revenue |
|
|
1,000 |
|
|
|
4,000 |
|
Total revenue |
|
|
556,000 |
|
|
|
722,000 |
|
Cost of goods sold |
|
|
231,000 |
|
|
|
280,000 |
|
Gross Profit |
|
|
325,000 |
|
|
|
442,000 |
|
Operating costs and expenses |
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
881,000 |
|
|
|
1,073,000 |
|
Research and development |
|
|
71,000 |
|
|
|
80,000 |
|
Total operating costs and expenses |
|
|
952,000 |
|
|
|
1,153,000 |
|
Loss from operations |
|
|
(627,000 |
) |
|
|
(711,000 |
) |
Other income (expense) |
|
|
|
|
|
|
|
|
Interest expense to related parties, net |
|
|
(62,000 |
) |
|
|
(24,000 |
) |
Total other income (expense) |
|
|
(62,000 |
) |
|
|
(24,000 |
) |
Net loss |
|
$ |
(689,000 |
) |
|
$ |
(735,000 |
) |
Basic and diluted net loss per share |
|
$ |
(0.01 |
) |
|
$ |
(0.01 |
) |
Shares used in computing basic and diluted net loss per share |
|
|
111,856,473 |
|
|
|
111,856,473 |
|
PURE Bioscience, Inc. |
||||||||||||||||||||
Condensed Consolidated Statement of Stockholders’ Deficiency |
||||||||||||||||||||
(Unaudited) |
||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Accumulated |
|
|
Total Stockholders’ |
|
||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Deficiency |
|
|||||
Balance July 31, 2024 |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,612,000 |
|
|
$ |
(136,595,000 |
) |
|
$ |
(2,864,000 |
) |
Share-based compensation expense - stock options |
|
|
— |
|
|
|
— |
|
|
|
57,000 |
|
|
|
— |
|
|
|
57,000 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(689,000 |
) |
|
|
(689,000 |
) |
Balance October 31, 2024 (Unaudited) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,669,000 |
|
|
$ |
(137,284,000 |
) |
|
$ |
(3,496,000 |
) |
|
|
Common Stock |
|
|
Additional Paid-In |
|
|
Accumulated |
|
|
Total Stockholders’ |
|
||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
|
Deficiency |
|
|||||
Balance July 31, 2023 |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,398,000 |
|
|
$ |
(133,245,000 |
) |
|
$ |
272,000 |
|
Share-based compensation expense - stock options |
|
|
— |
|
|
|
— |
|
|
|
80,000 |
|
|
|
— |
|
|
|
80,000 |
|
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(735,000 |
) |
|
|
(735,000 |
) |
Balance October 31, 2023 (Unaudited) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,478,000 |
|
|
$ |
(133,980,000 |
) |
|
$ |
(383,000 |
) |
PURE Bioscience, Inc. |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(Unaudited) |
||||||||
|
|
|
|
|
||||
|
|
Three Months Ended |
|
|||||
|
|
October 31, |
|
|||||
|
|
2024 |
|
|
2023 |
|
||
Operating activities |
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(689,000 |
) |
|
$ |
(735,000 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
|
Share-based compensation |
|
|
57,000 |
|
|
|
80,000 |
|
Depreciation |
|
|
— |
|
|
|
37,000 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(73,000 |
) |
|
|
(62,000 |
) |
Inventories |
|
|
(16,000 |
) |
|
|
(16,000 |
) |
Prepaid expenses |
|
|
(20,000 |
) |
|
|
(39,000 |
) |
Accounts payable and accrued liabilities |
|
|
178,000 |
|
|
|
274,000 |
|
Interest on note payable |
|
|
60,000 |
|
|
|
21,000 |
|
Net cash used in operating activities |
|
|
(503,000 |
) |
|
|
(440,000 |
) |
Financing activities |
|
|
|
|
|
|
|
|
Net proceeds from note payable to related parties |
|
|
500,000 |
|
|
|
785,000 |
|
Net cash provided by financing activities |
|
|
500,000 |
|
|
|
785,000 |
|
Net increase (decrease) in cash and cash equivalents, and restricted cash |
|
|
(3,000 |
) |
|
|
345,000 |
|
Cash and cash equivalents, and restricted cash at beginning of period |
|
|
424,000 |
|
|
|
1,170,000 |
|
Cash and cash equivalents, and restricted cash at end of period |
|
$ |
421,000 |
|
|
$ |
1,515,000 |
|
Reconciliation of cash and cash equivalents, and restricted cash to the condensed consolidated balance sheets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
346,000 |
|
|
$ |
1,440,000 |
|
Restricted cash |
|
|
75,000 |
|
|
|
75,000 |
|
Total cash and cash equivalents and restricted cash |
|
$ |
421,000 |
|
|
$ |
1,515,000 |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216457087/en/
Mark Elliott, VP Finance
PURE Bioscience, Inc.
Phone: 619-596-8600 ext.: 116
Source: PURE Bioscience, Inc.
FAQ
What were PURE Bioscience's Q1 2025 net product sales?
How much did PURE's net loss improve in Q1 2025 compared to Q1 2024?
What caused the decrease in PURE's Q1 2025 revenue?